We can’t show the full text here under this license. Use the link below to read it at the source.
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Heart and kidney effects of glucagon-like peptide 1 receptor drugs in people with and without type 2 diabetes
AI simplified
Abstract
GLP-1 receptor agonists (GLP-1RAs) significantly reduced major adverse cardiovascular events (MACEs) by 14% (OR 0.86) in a review of 13 trials involving 83,258 patients.
- GLP-1RAs are associated with a 13% reduction in all-cause mortality (OR 0.87).
- There is a 13% decrease in cardiovascular mortality (OR 0.87) with GLP-1RA treatment.
- Fatal stroke risk is reduced by 26% (OR 0.74), while non-fatal stroke risk is lowered by 13% (OR 0.87).
- Coronary revascularization procedures are reduced by 14% (OR 0.86) among patients treated with GLP-1RAs.
- A composite kidney outcome shows a significant reduction of 24% (OR 0.76) with GLP-1RA therapy.
- These benefits are consistent across different sexes, history of cardiovascular disease, body mass index, and kidney function levels.
AI simplified